Navigation Links
U.S. Study Shows Significant Improvement for Patients Suffering from Excessive Sweating with Topical Antiperspirant
Date:5/15/2009

ALBANY, N.Y., May 15 /PRNewswire/ -- Valeo Pharma announced today a new study recently published that demonstrated the efficacy and safety of Hydrosal(R), a novel high strength topical antiperspirant with 15% aluminum chloride and 2% salicylic acid in proprietary gel base for patients with moderate-to-severe hyperhidrosis (excessive sweating).

The study, conducted by Katherine Flanagan, MD and Dee Anna Glaser, MD at the Department of Dermatology at Saint Louis University School of Medicine, was published in the May issue of the Journal of Drugs in Dermatology (JDD). Of the thirty patients who were enrolled, 43% had tried high-strength antiperspirants previously. Patients were given Hydrosal and monitored at 4 and 12 weeks for efficacy and tolerability. They were instructed to apply a small amount of the gel at bedtime for seven days and twice per week or as tolerated thereafter.

Overall, 70% of participants demonstrated significant improvement with satisfaction of treatment and Hydrosal was well-tolerated with minimal side effects. Patients who had previously failed other high-strength antiperspirants also reported similar success. They also experienced significant improvements in quality of life including improvement in social and professional situations.

"The key to Hydrosal's effectiveness is the gel base -- it is unique and helps balance high efficacy and tolerability for patients with moderate to severe hyperhidrosis. Valeo is extremely pleased that these results have shown a significant improvement in the quality of life for these patients, so they can enjoy activities more and not have to worry about their excessive sweating," stated Steve Saviuk, President of Valeo Pharma.

To learn more about Hydrosal Professional, please visit www.hydrosalpro.com or contact Valeo Pharma at 866 694-0150.

To see press release go to http://myprgenie.com/1897


'/>"/>
SOURCE Valeo Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology: